MedTrace Logo

A Study in Taiwan Based on Medical Records That Looks at the Occurrence of Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Started LABA/LAMA or LAMA Treatment

NCT04011475 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1617

Last updated 2022-06-14

Study results available
· View outcomes & findings →

Summary

Study to collect the data on Chronic Obstructive Pulmonary Disease (COPD) patients who were administered with Long-Acting Beta-Agonist/ Long-Acting Muscarinic Antagonist (LABA/LAMA) (Fixed-dose Combination (FDC) or free combo) or LAMA treatment

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Tiotropium + Olodaterol

Spiolto®

DRUG

Other LABA/LAMA

tiotropium/olodaterol, indacaterol/glycopyrronium, vilanterol/umeclidinium

DRUG

LAMA

aclidinium bromide, glycopyrronium, tiotropium, umeclidinium

Sponsors & Collaborators

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-29
Primary Completion
2020-10-31
Completion
2020-10-31
FDA Drug
Yes

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04011475 on ClinicalTrials.gov